Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Author:
Funder
Narodowe Centrum Nauki
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology
Link
http://link.springer.com/content/pdf/10.1007/s40268-019-0269-9.pdf
Reference159 articles.
1. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7:766–72.
2. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006;46:189–213.
3. Sánchez-Serrano I. Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov. 2006;5:107–14.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.
5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.
Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severe renal failure requiring hemodialysis. A single-center experience;Oncohematology;2024-09-02
2. Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows;American Journal of Clinical Pathology;2024-07-20
3. Engineering small-molecule and protein drugs for targeting bone tumors;Molecular Therapy;2024-05
4. Ubiquitin-specific protease 8 controls B-cell proteostasis and survival representing a target in multiple myeloma;2024-04-26
5. The Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients—Real Life Experience in a Tertiary Romanian Hospital;Journal of Clinical Medicine;2024-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3